Natalie Banniettis, Michael Horn, Manish Sadarangani, Shrita M Patel, David Greenberg, Peninnah Oberdorfer, Nicola P Klein, Richard Rupp, Ron Dagan, Peter Richmond, Jessie Lumley, Wei Zhou, Yaru Shi, Gretchen Tamms, Kristen Feemster, Robert Lupinacci, Luwy Musey, Kara Bickham
BACKGROUND AND OBJECTIVES: Disease caused by Streptococcus pneumoniae is associated with considerable morbidity and mortality in children. Pneumococcal conjugate vaccines (PCVs) are well tolerated and effective at reducing pneumococcal disease caused by vaccine serotypes. VAXNEUVANCE (V114) is a 15-valent PCV containing 13 serotypes in Prevnar 13 (PCV13), plus serotypes 22F and 33F. This large phase 3 study evaluated safety and tolerability of V114 in infants. METHODS: In total, 2409 infants were randomized to receive V114 or PCV13 at 2, 4, 6, and 12 to 15 months of age...
June 13, 2023: Pediatrics